IgE-mediated allergy to recombinant human insulin in a diabetic.
A 63-year-old nonatopic female suffering from type II diabetes with severe local and systemic immediate-type allergic reactions to injections of different recombinant human insulin products has been reported. Skin testing as well as IgE measurements not only proved immediate-type sensitization to human insulin but also to porcine and bovine insulin which had never been administered and indicated immunological cross-reactivity. Cross-reactivity was proved by an IgE inhibition test. Independent of this reaction, the patient showed IgE-mediated sensitization to protamine.
Baur
X
X
Ordinariat und Zentralinstitut für Arbeitsmedizin Hamburg, Hamburg; Gemeinschaftspraxis Mannheim, Mannheim, Germany.
Bossert
J
J
Koops
F
F
D000918:Antibody Specificity / Q000276:immunology; D003429:Cross Reactions / Q000187:drug effects / Q000276:immunology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000139:chemically induced* / Q000276:immunology; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007073:Immunoglobulin E / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D007328:Insulin / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D012882:Skin Tests
D007004:Hypoglycemic Agents; D007074:Immunoglobulin G; D007328:Insulin; D011994:Recombinant Proteins; D007073:Immunoglobulin E